TF
PTGX icon

Trek Financial’s Protagonist Therapeutics PTGX Stock Holding History

Trek Financial’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-58,413
Closed -$2.82M – 446
2025
Q1 		$2.82M Buy
+58,413
New +$2.45M 0.2% 114

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Trek Financial's PTGX Position: Q2 2025 in Review

Trek Financial sold out of Protagonist Therapeutics (PTGX) in Q2 2025, closing a stake of 58,413 shares — an estimated $2.82M sold.

Trek Financial first reported a position in PTGX in Q1 2025 and held it in 1 quarter. The position peaked at $2.82M in Q1 2025. 272 funds tracked by Wall St. Rank hold PTGX as of Q2 2025.

  • Trek Financial reported no remaining Protagonist Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Trek Financial sold 58,413 Protagonist Therapeutics shares in Q2 2025, an estimated $2.82M.
  • Trek Financial first reported a position in Protagonist Therapeutics in Q1 2025 and held it in 1 quarter.
  • Trek Financial's Protagonist Therapeutics position peaked at $2.82M in Q1 2025.
  • 272 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2025.

Based on Trek Financial's 13F filing for Q2 2025, filed 13 Aug 2025.